摘要 |
The present invention relates to a method for the treatment of depression comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the level of one or more inflammatory markers in said patient is increased or abnormal. The present invention also relates to a method for the treatment of stress-mediated depression comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the level of one or more inflammatory markers is increased or abnormal in said patient. The present invention also relates to a method for the treatment of depression or the amelioration of one or more depressive symptoms comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the clinical presentation of one or more symptoms of depression are the physiological effect of a general medical condition. Furthermore the present also relates to a method for testing the therapeutic effectiveness of a compound in the treatment of depression or reducing the symptoms of depression comprising measuring the amount of one or more inflammatory markers in a sample from a patient before said compound is administered to the patient and comparing with the amount of said one or more inflammatory markers in a sample from the same patient after administration of said compound to the patient.
|